SAN DIEGO, CA--(Marketwired - May 31, 2013) - NuVasive, Inc. (
Initially released in a limited launch around the United States, the NuVasive MAS PLIF is now available for patients and surgeons in Australia, Switzerland, Italy, Germany, and the United Kingdom.
Surgeons who played a key role in the innovation and development of the procedure have been instrumental in training other surgeons in both of the NuVasive San Diego and New Jersey state-of-the-art cadaveric labs.
"MAS PLIF is a unique procedure that offers truly reproducible results that embrace traditional surgical principles," said Nitin Khanna, M.D. "The beauty is in the simplicity of the system, which all surgeons can implement in their practice."
The minimally disruptive procedure was uniquely developed by surgeon design and product development teams to cohesively output the access, fixation, interbody, graft delivery, and neuromonitoring components specific to the procedure.
"The integration effort is undeniable in the final output of the system," said Gurvinder Deol, M.D. "Every nuance, from the unique retractor blades, the laterally placed interbody cages, the modular screw option, and the insulated pedicle prep instruments make for a seamless, safe, and reproducible procedure."
MAS® PLIF is designed to eliminate the need to retract back muscles as wide laterally as a traditional, or "open," PLIF, therefore requiring a smaller incision. By minimizing the amount of muscle disruption, the procedure is intended to help reduce postoperative approach-related muscle pain and to enable a faster recovery for the patient.
For NuVasive press materials please visit: http://www.nuvasive.com/about-us/newsroom/
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.
NuVasive offers a comprehensive spine portfolio of over 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company places a large focus on clinical research and support of the Society of Lateral Access Surgery, or SOLAS®, to expand the body of clinical evidence in support of NuVasive's minimally disruptive solutions and to drive adoption of its techniques. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-Up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to those risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.